Table 2.
Characteristics of 389 patients with SARS-CoV-2 treated with antiviral therapies by treatment administered.
| Variables | Molnupiravir (n = 242) |
Nirmatrelvir/Ritonavir (n= 39) |
Remdesivir (n = 108) |
p-Value | |
|---|---|---|---|---|---|
| Males, n (%) | 135 (55.8) | 22 (56.4) | 60 (55.6) | 1.00 | |
| Median (IQR) age, years | 75 (64–83) | 65 (53–79) | 77 (68–84) | <0.00011 | |
| Patient provenance | Emergency room | 135 (55.8) | 16 (41.0) | 44 (40.7) | <0.0001 |
| Ward | 78 (32.3) | 14 (35.9) | 64 (59.3) | ||
| Day-Hospital | 29 (12.0) | 9 (23.1) | 0 | ||
| Comorbidities | |||||
| Immunodeficit, n (%) | 42 (17.4) | 13 (33.3) | 11 (10.2) | 0.004 | |
| Neurodevelopmental/neurodegenerative diseases, n (%) | 54 (22.3) | 5 (12.8) | 41 (38.0) | 0.002 | |
| Dementia, n (%) | 24 (9.9) | 1 (2.6) | 20 (18.5) | 0.01 | |
| Cerebrovascular events, n (%) | 26 (10.7) | 2 (5.1) | 23 (21.3) | 0.01 | |
| Cardiovascular diseases, n (%) | 110 (45.5) | 8 (20.5) | 44 (40.7) | 0.01 | |
| Heart failure, n (%) | 370 (32.3) | 241 (29.8) | 129 (38.4) | 0.005 | |
| Previous myocardial infarction, n (%) | 147 (12.8) | 101 (12.5) | 46 (13.7) | 0.58 | |
| Median (IQR) CCI | 5 (4–7) | 4 (3–6) | 6 (4–7) | 0.022 | |
| Other | |||||
| Hospital infection, n (%) | 67 (27.7) | 11 (28.2) | 59 (54.6) | <0.0001 | |
| Disease progression, n (%) | 18 (7.4) | 3 (7.7) | 16 (14.8) | 0.09 | |
IQR: interquartile range; CCI: Charlson comorbidity index; PCT: procalcitonin; eGFR: estimated glomerular filtration rate; CRP: C-reactive protein. 1 Molnupiravir VS. Nirmatrelvir/ritonavir p = 0.001; Nirmatrelvir/ritonavir VS. Remdesivir p = 0.0004; 2 Molnupiravir VS. Nirmatrelvir/ritonavir p = 0.009; Nirmatrelvir/ritonavir VS. Remdesivir p = 0.01.